Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.
The statistics are staggering and well-known. Despite an increasing pipeline of drugs targeting rare diseases, 95 percent of the 7,000 disorders classified as rare still have no indicated treatment option. Eighty percent of rare diseases are genetically based, and more than half of the 30 million Americans affected by rare disorders are children. Rare diseases can take five to seven years to be accurately diagnosed, partly because they are inherently difficult to identify and because there are relatively few physicians equipped to recognize and design an appropriate treatment plan for a disorder that will, at most, affect 200,000 people (but often far fewer).
Murder, suicide, car crashes, and addiction have all contributed to a spike in deaths among U.S. children and teens in recent years, a government study suggests.
Amgen Inc. said a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.
Nearly 20 percent of American adolescents, or one in five, has suffered a concussion, according to newly released statistics.